Congenital resistance to activated protein C in patients with lupus anticoagulants: evaluation of two functional assays.


The R506Q mutation ("Factor V Leiden") is responsible for the resistance to activated Protein C (aPCR), that is evaluated by coagulation tests. Such tests cannot be used in patients with lupus anticoagulants (LAs), due to the interfering effect exerted by these antibodies on "in vitro" phospholipid-dependent coagulation tests. For this reason, assays have… (More)

1 Figure or Table


  • Presentations referencing similar topics